- Home
- CRWD vs BMY Comparison
CRWD vs BMY Comparison
Compare CRWD & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | BMY |
|---|---|---|
| Founded | 2011 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.7B | 115.3B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CRWD | BMY |
|---|---|---|
| Price | $595.60 | $56.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 48 | 15 |
| Target Price | ★ $507.00 | $61.73 |
| AVG Volume (30 Days) | 2.5M | ★ 8.7M |
| Earning Date | 06-02-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 4.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,812,005,000.00 | N/A |
| Revenue This Year | $24.85 | N/A |
| Revenue Next Year | $21.40 | N/A |
| P/E Ratio | ★ N/A | $17.26 |
| Revenue Growth | ★ 21.71 | N/A |
| 52 Week Low | $342.72 | $42.52 |
| 52 Week High | $583.78 | $62.89 |
Technical Indicators
Market Signals| Indicator | CRWD | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 82.59 | 44.86 |
| Support Level | $477.12 | $53.88 |
| Resistance Level | N/A | $57.04 |
| Average True Range (ATR) | 21.13 | 1.27 |
| MACD | 11.97 | -0.07 |
| Stochastic Oscillator | 98.83 | 25.77 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.